<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362801">
  <stage>Registered</stage>
  <submitdate>23/07/2012</submitdate>
  <approvaldate>26/09/2012</approvaldate>
  <actrnumber>ACTRN12612001035819</actrnumber>
  <trial_identification>
    <studytitle>The Effect of Prolonged Glucagon-like Peptide 1 Infusion on Gastric Emptying in Healthy Volunteers</studytitle>
    <scientifictitle>The Effect of Prolonged Glucagon-like Peptide 1 Infusion on Gastric Emptying in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hyperglycaemia</healthcondition>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Critical Illness Induced Hyperglycaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1: intermittent GLP-1 infusion (0.8 pmol/kg/min over 2x4.5 hours separated by 19 hours) Arm 2: Acute GLP-1 infusion (0.8 pmol/kg/min over 4.5 hours)Arm 3: prolonged GLP-1 infusion(0.8 pmol/kg/min over 24 hours) Treatment order is randomised with a washout period of at least 3 days.</interventions>
    <comparator>placebo (normal saline IV at 4.5 hours) Treatment order is randomised with a washout period of at least 3 days</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Scintigraphic Measurement of Gastric Emptying</outcome>
      <timepoint>0,5,15,30,45,60,90,120,150,180,210,240 mins</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood glucose analysis</outcome>
      <timepoint>-30, 0, 30, 60, 90, 120, 180, 300, 420, 480, 600, 660, 780, 900, 1020, 1140, 1260, 1380, 1410, 1440(24hrs), 1470, 1500, 1530, 1560, 1620 and 1680 min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Glucagon - blood analysis</outcome>
      <timepoint>-30, 0, 30, 60, 120, 180, 420, 480, 660, 900, 1140, 1410 1440, 1470, 1500, 1530, 1560, 1620 and 1680  min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>GLP-1 - blood analysis</outcome>
      <timepoint>-30, 0, 30, 60, 120, 180, 420, 480, 660, 900, 1140, 1410 1440, 1470, 1500, 1530, 1560, 1620 and 1680  min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>GIP - blood analysis</outcome>
      <timepoint>-30, 0, 30, 60, 120, 180, 420, 480, 660, 900, 1140, 1410 1440, 1470, 1500, 1530, 1560, 1620 and 1680  min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pancreatic Polypeptide - blood analysis</outcome>
      <timepoint>-30, 0, 30, 60, 120, 180, 420, 480, 660, 900, 1140, 1410 1440, 1470, 1500, 1530, 1560, 1620 and 1680  min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Insulin blood analysis</outcome>
      <timepoint>-30, 0, 30, 60, 90, 120, 180, 420, 480, 660, 900, 1140, 1410, 1440(24hrs), 1470, 1500, 1530, 1560, 1620 and 1680 min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>C-peptide blood analysis</outcome>
      <timepoint>-30, 0, 30, 60, 90, 120, 180, 420, 480, 660, 900, 1140, 1410, 1440(24hrs), 1470, 1500, 1530, 1560, 1620 and 1680 min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Nausea - VAS</outcome>
      <timepoint>0, 30,45,60,75,90,120,150,180,210,240,300,360,450,510,630,690,810,930,1050,1170,1140, 1470,1500,1530,1560,1590,1650 mins</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>appetite - VAS</outcome>
      <timepoint>0, 30,45,60,75,90,120,150,180,210,240,300,360,450,510,630,690,810,930,1050,1170,1140, 1470,1500,1530,1560,1590,1650 mins</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Healthy
2.Normal gastric functioning</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>- Inability to give informed consent,
- Radiation exposure for research purposes in the past 12 months,
- The ARPANSA guidelines published by the Australian Government entitled Code of Practice Exposure of Humans to Ionizing Radiation for Research Purposes States that the dose constraints for a research participant is 5mSv per year and 10mSv for a 5 year period.
- History of diabetes,
- HbA1c &gt;6.0,
- Taking medication that are known to effect gastrointestinal motility,
- Taking medication effecting blood glucose,
- Creatinine Clearance &lt;100 ml/min (men), 90 ml/min (women)
- Pregnancy, 
- Ferritin level &lt; 20microg/L
- Previous surgery on the small intestine, 
- Smoking &gt;10 cigarettes per day
- Alcohol  &gt;20g per day
- Because of concerns of cumulative life time exposure to radiation, we will directly screen all volunteers as to their previous radiation exposure, and will exclude any volunteer who has received 3 or more examinations using a computerized tomogram and/or 10 or more examinations using standard x-rays.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Hospital pharmacy (separate department) uses a web based randomisation program called research randomiser(www.randomizer.org)  to allocate when the intervention is given</concealment>
    <sequence>permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>19/06/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Mahesh Umapathysivam</primarysponsorname>
    <primarysponsoraddress>Intensive Care Research
Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Adam Deane</sponsorname>
      <sponsoraddress>Intensive Care Research
Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study aims to identify whether there is reduction in the effect of GLP-1 on gastric emptying with prolonged infusion of GLP-1.
Hypothesis
The GLP-1's effect of slowing gastric emptying will be reduced over time.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committe</ethicname>
      <ethicaddress>Research Ethics Committee,
Level 3, Hanson Institute
Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000</ethicaddress>
      <ethicapprovaldate>30/05/2012</ethicapprovaldate>
      <hrec>120433</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mahesh Umapathysivam</name>
      <address>Intensive Care Research
Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000</address>
      <phone>+61 433 681 614</phone>
      <fax />
      <email>a1164300@student.adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mahesh Umapathysivam</name>
      <address>Intensive Care Research
Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000</address>
      <phone>+61 433 681 614</phone>
      <fax />
      <email>a1164300@student.adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>